Li Hongliang, Yu Xichun, Cicala Maria Verena, Mantero Franco, Benbrook Alexandria, Veitla Vineet, Cunningham Madeleine W, Kem David C
Endocrinology Section, Department of Medicine, University of Oklahoma Health Sciences Center and VA Medical Center, Oklahoma City, OK, USA; Heart Rhythm Institute, Department of Medicine, University of Oklahoma Health Sciences Center and VA Medical Center, Oklahoma City, OK, USA.
Endocrinology Unit, Department of Medicine, University of Padua, Padua, Italy.
J Am Soc Hypertens. 2015 Jan;9(1):15-20. doi: 10.1016/j.jash.2014.10.009. Epub 2014 Oct 23.
Autoantibodies to the angiotensin II type 1 receptor (AT1R) have been reported in patients with primary aldosteronism, including aldosterone producing adenoma (APA) and idiopathic adrenal hyperplasia (IAH). Sera from 25 primary aldosteronism subjects (12 with IAH and 13 with APA) and 15 normotensive control subjects were assayed for AT1R autoantibodies by enzyme-linked immunosorbent assay and an AT1R-transfected cell-based bioassay. Nine of 12 IAH subjects (75%) and six of 13 APA subjects (46%) were positive for AT1R autoantibodies in the bioactivity assay. The mean AT1R autoantibody activity for the IAH and APA subjects was significantly greater than controls (P < .001 and P < .01, respectively), and this in vitro activity was suppressed by the AT1R blocker losartan. None of the controls had significant AT1R autoantibody activity. Enzyme-linked immunosorbent assay values were less sensitive but were positive in some subjects with IAH and APA. The mean arterial pressure of these primary aldosteronism subjects correlated modestly with AT1R autoantibody activity. These data confirm the presence of active AT1R autoantibodies in a high percentage of subjects with primary aldosteronism irrespective of their underlying etiology. These observations have both pathophysiological and clinical implications.
原发性醛固酮增多症患者,包括醛固酮瘤(APA)和特发性肾上腺增生(IAH)患者中,已报告存在血管紧张素II 1型受体(AT1R)自身抗体。采用酶联免疫吸附测定法和基于AT1R转染细胞的生物测定法,检测了25例原发性醛固酮增多症患者(12例IAH患者和13例APA患者)以及15例血压正常对照者血清中的AT1R自身抗体。在生物活性测定中,12例IAH患者中有9例(75%)、13例APA患者中有6例(46%)的AT1R自身抗体呈阳性。IAH患者和APA患者的AT1R自身抗体平均活性显著高于对照组(分别为P <.001和P <.01),且这种体外活性被AT1R阻滞剂氯沙坦所抑制。所有对照者均无显著的AT1R自身抗体活性。酶联免疫吸附测定值敏感性较低,但部分IAH和APA患者呈阳性。这些原发性醛固酮增多症患者的平均动脉压与AT1R自身抗体活性呈适度相关。这些数据证实,无论潜在病因如何,高比例的原发性醛固酮增多症患者体内存在活性AT1R自身抗体。这些观察结果具有病理生理学和临床意义。